drugset / Trial / NCT04428632
Oral Berotralstat Expanded Access Program
Summary
This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | berotralstat | Small molecule | 150 mg | Oral |